Practical approaches to neurogenetic disease

Journal of Neuro-Ophthalmology

Volumn 22, Issue 4, 2002, Pages 297-304

  Lynch, David R ^a,b   Farmer, Jennifer ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; CYTOSINE; GUANINE;

ATAXIA; AUTOSOMAL DOMINANT DISORDER; CLASSIFICATION; CLINICAL FEATURE; CONFERENCE PAPER; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; FRIEDREICH ATAXIA; GENETIC COUNSELING; GENETIC DISORDER; HUMAN; HUNTINGTON CHOREA; MOLECULAR GENETICS; MYOTONIC DYSTROPHY; NEUROGENETIC DISEASE; NEUROOPHTHALMOLOGY; OCULOPHARYNGEAL MUSCULAR DYSTROPHY; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SPINOCEREBELLAR DEGENERATION;

EID: 0036897160     PISSN: 10708022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041327-200212000-00007     Document Type: Conference Paper

References (55)

1. Paulson H, Ammache Z. Ataxia and hereditary disorders. Neurol Clin 2001;19:759-82.
2. Moschner C, Perlman S, Baloh RW. Comparison of oculomotor findings in the progressive ataxia syndromes. Brain 1994;117:15-25.
3. Subramony SH, Filla A. Autosomal dominant spinocerebellar ataxias ad infinitum? Neurology 2001;56:287-9.
4. Tan EK, Ashizawa T. Genetic testing in spinocerebellar ataxias: Defining a clinical role. Arch Neurol 2001;58:191-5.
5. Oheam E, Holmes SE, Calvert PC, et al. SCA-12: Tremor with cerebellar and cortical atrophy is associated with a CAG repeat expansion. Neurology 2001;56:299-303.
6. Gwinn-Hardy K, Singleton A, O'Suilleabhain P, et al. Spinocerebellar ataxia type 3 phenotypically resembling parkinson disease in a black family. Arch Nettrol 2001;58:296-9.
7. Tuite PJ, Rogaeva EA, St George-Hyslop PH, et al. Doparesponsive parkinsonism phenotype of Machado-Joseph disease: Confirmation of 14q CAG expansion. Ann Neurol 1995;38:684-7.
8. Schols L, Kruger R, Amoiridis G, et al. Spinocerebellar ataxia type 6: Genotype and phenotype in German kindreds. J Neurol Neurosurg Psychiatry 1998;64:67-73.
9. Geschwind DH, Perlman S, Grody WW, et al. Friedreich's ataxia GAA repeat expansion in patients with recessive or sporadic ataxia. Neurology 1997;49:1004-9.
10. Fernandez M, McClain ME, Martinez RA, et al. Late-onset SCA2:33 CAG repeats are sufficient to cause disease. Neurology 2000;55:569-72.
11. Johnson WG. Late-onset neurodegenerative diseases-the role of protein insolubility, J Anat 2000;196:609-16.
12. Chen M, Ona VO, Li M, et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 2000;6:797-801.
13. Huntington Study Group T. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 2001;57:397-404.
14. Harding AE. Friedreich's Ataxia: A clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features. Brain 1981;104:589-620.
15. Pandolfo M. Molecular pathogenesis of Friedreich ataxia. Arch Neurol 1999;56:1201-8.
16. Furman JM, Perlman S, Baloh RW. Eye movements in Friedreich's ataxia. Arch Neurot 1983;40:343-6.
17. Givre SJ, Wall M, Kardon RH. Visual loss and recovery in a patient with Friedreich ataxia. J Neuro-Ophthalmol 2000;20:229-33.
18. Carroll WM, Kriss A, Baraitser M, et al. The incidence and nature of visual pathway involvement in Friedreich's ataxia. A clinical and visual evoked potential study of 22 patients. Brain 1980;103:413-34.
19. McCormack ML, Guttmann RP, Schumann M, et al. Frataxin point mutations in two patients with Friedreich's ataxia and unusual clinical features. J Neurol Neurosurg Psychiatry 2000;68:661-4.
20. Campuzano V, Montermini L, Molto MD, et al. Friedreich's ataxia: Autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 1996;271:1423-7.
21. Ohshima K, Montermini L, Wells RD, et al. Inhibitory effects of expanded GAA.TTC triplet repeats from intron I of the Friedreich Ataxia gene on transcription and replication in vivo. J Biol Chem 1998;273:14588-95.
22. Campuzano V, Montermini L, Lutz Y, et al. Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. Hum Molec Genet 1997;6:1771-80.
23. Montermini L, Richter A, Morgan K, et al. Phenotypic variability in Friedreich ataxia: Role of the associated GAA triplet repeat expansion. Ann Neurol 1997;41:675-82.
24. Lhatoo SD, Rao DG, Kane NM, et al. Very late onset Friedreich's ataxia presenting as spastic tetraparesis without ataxia or neuropathy. Neurology 2001;56:1776-7.
25. Gellera C, Pareyson D, Castellotti B, et al. Very late onset Friedreich's ataxia without cardiomyopathy is associated with limited GAA expansion in the X25 gene. Neurology 1997;49:1153-5.
26. Bidichandani SI, Garcia CA, Patel PI, et al. Very late-onset Friedreich ataxia despite large GAA triplet repeat expansions. Arch Neurol 2000;57:246-51.
27. Bidichandani SI, Ashizawa T, and Patel PI. Atypical Friedreich Ataxia caused by compound heterozygosity for a novel missense mutation and the GAA triplet-repeat expansion. Am J Hum Genet 1997;60:1251-6.
28. Cossee M, Durr A, Schmitt M, et al. Friedreich ataxia: Point mutations and clinical presentation of compound heterozygotes. Ann Neurol 1999;45:200-6.
29. Forrest SM, Knight M, Delatycki MB, et al. The correlation of clinical phenotype in Friedreich ataxia with the site of point mutations in the FRDA gene. Neurogenetics 1998;1:253-7.
30. McCabe DJ, Ryan F, Moore DP, et al. Typical Friedreich's ataxia without GAA expansions and GAA expansion without typical Friedreich's ataxia, J Neurol 2000;247:346-55.
31. Cavalier L, Ouahchi K, Kayden HJ, et al. Ataxia with isolated vitamin E deficiency: Heterogeneity of mutations and phenotypic variability in a large number of families. Am J Hum Genet 1998;62:301-10.
32. Adamec J, Rusnak F, Owen WG, et al. Iron-dependent selfassembly of recombinant yeast frataxin: implications for Friedreich Ataxia. Am J Hum Genet 2000;67:549-62.
33. Gordon N. Friedreich's ataxia and iron metabolism. Brain Dev 2000;22:465-8.
34. Wilson RB, Lynch DR, Farmer JM, et al. Increased serum transferrin receptor concentrations in Friedreich ataxia. Ann Neurol 2000; 47:659-61.
35. Patel PI, Isaya G. Friedreich ataxia: From GAA triplet-repeat expansion to frataxin deficiency. Am J Hum Genet 2001;69:15-24.
36. Babcock M, de Silva D, Oaks R, et al. Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin. Science 1997;276:1709-12.
37. Rustin P, von Kleist-Retzow JC, Chantrel-Groussard K, et al. Effect of idebenone on cardiomyopathy in Friedreich's ataxia: A preliminary study. Lancet 1999;354:477-9.
38. Wong A, Yang J, Cavadini P, et al. The Friedreich's ataxia mutation confers cellular sensitivity to oxidant stress which is rescued by chelators of iron and calcium and inhibitors of apoptosis. Hum Molec Genet 1999;8:425-30.
39. Vorgerd M, Schols L, Hardt C, et al. Mitochondrial impairment of human muscle in Friedreich ataxia in vivo. Neuromuscul Disord 2000;10:430-5.
40. Lodi R, Hart PE, Rajagopalan B, et al. Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia. Ann Neurol 2001;49:590-6.
41. Meola G. Clinical and genetic heterogeneity in myotonic dystrophies. Muscle Nerve 2000;23:1789-99.
42. Lieberman AP, Fischbeck, KH. Triplet repeat expansion in neuromuscular disease. Muscle Nerve 2000;23:843-50.
43. Ashizawa T, Hejtmancik JF, Lui J, et al. Diagnostic value of ophthalmologic findings in myotonic dystropy: Comparison with risks calculated by haplotype analysis of closely linked restriction fragment length polymorphisms. Am J Med Genet 1992;42:55-60.
44. Goto I, Kanazawa Y, Kobayashi T, et al. Oculopharyngeal myopathy with distal and cardiomyopathy. J Neurol Neurosurg Psychiatry 1977;40:600-607.
45. Siderowf A. Parkinson's disease: Clinical features, epidemiology and genetics. Neurol Clin 2001;19:565-78.
46. Vaughan JR, Davis MB, Wood NW. Genetics of parkinsonism: A review. Ann Hum Genet 2001;65:111-26.
47. Giasson BI, Murray IV, Trojanowski JQ, et al. A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J Biol Chem 2001;276:2380-6.
48. Paxinou E, Chen Q, Weisse M, et al. Induction of alpha-synuclein aggregation by intracellular nitrative insult. J Neurosci 2001;21: 8053-61.
49. Farrer M, Chan P, Chen R, et al. Lewy bodies and parkinsonism in families with parkin mutations. Ann Neurol 2001;50:293-300.
50. Zhang Y, Dawson VL, Dawson TM. Oxidative stress and genetics in the pathogenesis of Parkinson's disease. Neurobiol Dis 2000;7: 240-250.
51. Orth M, Schapira AH. Mitochondria and degenerative disorders. Am J Med Genet 2001;106:27-36.
52. Farrer M, Maraganore, DM, Lockhart, P, et al. alpha-Synuclein gene haplotypes are associated with Parkinson's disease. Hum Mol Genet 2001;10:1847-51.
53. Nygaard TG, Trugman JM, de Yebenes JG, et al. Dopa-responsive dystonia: The spectrum of clinical manifestations in a large North American family. Neurology 1990;40:66-9.
54. Paulson GW and Prior, TW. Issues related to DNA testing for Huntington's disease in symptomatic patients. Semin Neurol 1997;17: 235-8.
55. Anonymous. Points to consider: Ethical, legal, and psychosocial implications of genetic testing in children and adolescents. Am J Hum Genet 1995;57:1233-41.